Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01596140 · ClinicalTrials.gov registry record · Phase 1
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01596140: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01596140 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01596140, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with either everolimus or temsirolimus. The safety of these drug combinations will also be studied. Vemurafenib is designed to block BRAF inside the cancer cells, which is a mutation that is involved in cancer cell growth. Temsirolimus and everolimus are designed to block the growth of cancer cells, which may cause cancer cells to die.
Interventions
- DRUG Everolimus
- DRUG Vemurafenib
- DRUG Temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-12-18 |
| Est. Completion | 2020-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01596140
The ClinicalTrials.gov registry entry for NCT01596140 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Everolimus is the first listed.
NCT01596140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01596140 about?
NCT01596140 is a clinical study titled "Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer". The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with either everolimus or temsirolimus. The safety of these drug combinations will also be studied. Vemurafenib is designed to block BRAF inside the cancer cells, which is ...
What is the current status of trial NCT01596140?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2012-12-18. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT01596140?
The interventions under investigation include: Everolimus (DRUG), Vemurafenib (DRUG), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT01596140?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.